Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population

Papp, Kim; Valenzuela, Fernando; Poulin, Yves; Bernstein, Geula; Wasel, Norman
July 2010
Journal of Cutaneous Medicine & Surgery;Jul/Aug2010, Vol. 14 Issue 4, p167
Academic Journal
Background: Limited data are available on the epidemiologic features of psoriasis in Canada. Objective: To investigate the epidemiologic features and burden of moderate-to-severe psoriasis in a Canadian population. Methods: An online survey was conducted using a consumer panel. Eligible respondents indicated a diagnosis of psoriasis and plaque-type psoriasis of at least moderate severity. Eligibility was validated according to self-reported body surface area (BSA) involvement, sensitive areas affected, and/or current treatment. Results: Of the 514 respondents who completed the survey, 62% estimated a BSA involvement of ≥ 3% within the past 5 years. Onset of psoriasis occurred earlier in females than in males. Nail involvement was more commonly reported in individuals with psoriatic arthritis compared to those without. Several symptoms were more likely described as "constantly" or "near constantly" experienced by females than by males. Comorbidities commonly reported were hypertension, dyslipidemia, and overweight or obesity. Conclusions: The findings are consistent with a substantial burden attributed to moderate-to-severe plaque psoriasis in a Canadian population.


Related Articles

  • Psoriasis patients work better with etanercept.  // PharmacoEconomics & Outcomes News;9/15/2012, Issue 662, p9 

    The article discusses the results of the Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept in Psoriasis (CAN-EASE) trial which shows that etanercept treatment improves work productivity and reduces healthcare resource use in patients with plaque psoriasis.

  • The Burden of Psoriasis and Barriers to Satisfactory Care: Results from a Canadian Patient Survey. Mahler, Ronald; Jackson, Christine; Ijacu, Horia // Journal of Cutaneous Medicine & Surgery;Nov/Dec2009, Vol. 13 Issue 6, p283 

    Background: The physical, mental, social, and financial burdens experienced by Canadians with psoriasis are relatively unexplored. Objective: To gain an understanding of the impact of psoriasis on Canadians. Methods: An online survey, "Stand Up and Speak Out," was provided to Psoriasis Education...

  • Resetting the Research Agenda for Psoriasis. Chalmers, Robert JG; Griffiths, Christopher EM // Journal of Investigative Dermatology;May2003, Vol. 120 Issue 5, pix 

    Comments on the European Dermato-Epidemiology Network survey of randomized controlled trials (RCT) in psoriasis. Performance of the dermatology community; Efforts to evaluate treatments for psoriasis; Evaluation of RCT in psoriasis.

  • A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients. Wasel, Norman; Poulin, Yves; Andrew, Robin; Chan, Daphne; Fraquelli, Elisa; Papp, Kim // Journal of Cutaneous Medicine & Surgery;Nov/Dec2009, Vol. 13 Issue 6, p294 

    Background: Few population studies of individuals living with psoriasis have been performed in Canada. Objective: The objective of this survey was to understand the severity and impact of psoriasis on the lives of Canadian patients. Methods: An online survey was conducted using a consumer panel....

  • The AWARE Study: Methodology and Baseline Characteristics. Bissonnette, Robert; Searles, Gordon; Landells, Ian; Shear, Neil H.; Papp, Kim; Lui, Harvey; Gulliver, Wayne P.F.; Lynde, Charles // Journal of Cutaneous Medicine & Surgery;Dec2009 Supplement, Vol. 13 Issue S3, pS113 

    Background: Alefacept was the first biologic therapy approved by Health Canada for the treatment of moderate to severe chronic plaque psoriasis and is used either alone or as part of combination therapy. Objective: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter,...

  • Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Ren, Vicky; Dao Jr, Harry // Clinical, Cosmetic & Investigational Dermatology;2013, Vol. 6, p75 

    Background: Psoriasis is a debilitating autoimmune skin disease that affects 2%-3% of the world's population. Patients with moderate-to-severe plaque psoriasis suffer from a decreased quality of life as well as comorbidities. Newer biological agents have been shown to be more effective than...

  • EPIMAG: International Cross-Sectional Epidemiological Psoriasis Study in the Maghreb. Ammar-Khodja, Aomar; Benkaidali, Ismail; Bouadjar, Bakar; Serradj, Amina; Titi, Abdelhamid; Benchikhi, Hakima; Amal, Said; Hassam, Badreddine; Sekkat, Abdelhak; Mernissi, Fatima Zahra; Mokhtar, Inçaf; Dahoui, Raouf; Denguezli, Mohamed; Doss, Nejib; Turki, Hamida; Mokhtar, Inçaf // Dermatology (10188665);Jul2015, Vol. 231 Issue 2, p134 

    Background: Psoriasis is a common skin disorder that is characterized by red plaques covered with silvery scales and is associated with considerable psychosocial impact. It has been described in several studies worldwide, but specific data from the Maghreb (Algeria, Morocco and...

  • Emerging targeted therapies for plaque psoriasis -- impact of ixekizumab. Kazemi, Tiana; Farahnik, Benjamin; Koo, John; Beroukhim, Kourosh // Clinical, Cosmetic & Investigational Dermatology;Apr2017, Vol. 10, p133 

    Background: Recent studies into the pathogenesis of psoriasis have identified the importance of interleukin 17 (IL-17) in disease activity and have thus provided a new target for biologic therapy. Ixekizumab, the most recent US Food and Drug Administration (FDA)-approved anti-IL-17 biologic...

  • Epidemiology of Psoriasis. Naldi, Luigi // Current Drug Targets - Inflammation & Allergy;Jun2004, Vol. 3 Issue 2, p121 

    The prevalence of psoriasis is relatively high in the general population, ranging between 0.6% and 4.8%, mainly as a result of chronicity and the absence of a cure. Although genetic-environmental interaction has been proposed as a model for the causation of psoriasis, the evidence for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics